CN102935133A - Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102935133A CN102935133A CN2012105238765A CN201210523876A CN102935133A CN 102935133 A CN102935133 A CN 102935133A CN 2012105238765 A CN2012105238765 A CN 2012105238765A CN 201210523876 A CN201210523876 A CN 201210523876A CN 102935133 A CN102935133 A CN 102935133A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- rheumatic arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 201000003068 rheumatic fever Diseases 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000012567 medical material Substances 0.000 claims description 19
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 240000000559 Albizia odoratissima Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 241000110637 Cuscuta chinensis Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000096284 Gynochthodes officinalis Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241000157373 Uncaria rhynchophylla Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000013642 negative control Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 206010063560 Excessive granulation tissue Diseases 0.000 description 7
- 210000001126 granulation tissue Anatomy 0.000 description 7
- 235000009161 Espostoa lanata Nutrition 0.000 description 6
- 240000001624 Espostoa lanata Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000220433 Albizia Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950005162 benexate Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Abstract
The invention provides a traditional Chinese medicine composition for treating rheumatic arthritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of angelica sinensis, 10 to 20 parts of salvia miltiorrhiza, 40 to 60 parts of morinda officinalis, 10 to 20 parts of polygonum multiflorum, 15 to 25 parts of radix paeoniae alba, 15 to 25 parts of radix paeoniae rubra, 10 to 20 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of teasel root, 10 to 20 parts of uncaria rhynchophylla, 30 to 50 parts of herba epimedii, 15 to 25 parts of cortex albiziae, 15 to 25 parts of pericarpium citri reticulatae, 15 to 25 parts of cuscuta chinensis, 30 to 50 parts of dogwood, 15 to 25 parts of astragalus mongholicus, 10 to 20 parts of poria cocos, and 10 to 20 parts of liquorice. The traditional Chinese medicine composition has the effects of reinforcing Qi and nourishing blood, dispelling wind and eliminating dampness, expelling wind to dredge collateral, reducing phlegm and removing blood stasis, so that the purpose of treating rheumatic arthritis can be achieved. The invention also discloses a preparation method and application of the traditional Chinese medicine composition.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition that is used for the treatment of rheumatic arthritis and its preparation method and application.
Background technology
Rheumatic arthritis (rheumatoid arthritis) is a kind of common acute or chronic ICT.Can repeatedly show effect and involve heart.Clinical miserable take joint and muscle migration, heavily work, pain is as feature.Belong to allergic disease.One of main manifestations of rheumatic fever, mainly with febris acuta and arthralgia onset.
Rheumatism is at the chronic pain that medically is articulations digitorum manus and surrounding soft tissue's unknown cause thereof.Rheumatism refers to that then different the but common ground of a large class cause of disease for involving joint and surrounding soft tissue, comprises the disease of flesh, ligament, synovial bursa, fascia.Arthropathy has pain outward still with swelling and moving obstacle, is outbreak and alleviates the chronic course of disease alternately.Because patient's blood circulation is obstructed, cause muscle or organize needed nutrition to carry by blood circulation, cause patient's muscle to lack nutrition and accelerated ageing becomes stiff, serious meeting causes patient's muscle and blood vessel atrophy, some patients were and can occur that disable in the joint and viscera function is depleted.The Drug therapys such as present domestic clinical nonsteroidal anti-inflammatory agent commonly used all are chemical drugss, and side effect is large, and safety day by day is subject to people and pays close attention to.For this reason, need to develop the needs that how safe and effective treatment rheumatic arthritis medicine satisfies clinical treatment.In rheumatic arthritis medication market share critical role, because the Chinese medicine side effect is little, determined curative effect is applicable to long-term prescription to Chinese medicine, has adapted to the easily characteristics of recurrence of rheumatic arthritis, and clinical practice is very extensive.People in the urgent need to a kind of effective, confirmed to rise the Chinese medicine composition of the treatment rheumatic arthritis of good result by most people.
Summary of the invention
Goal of the invention: in order to address the above problem, the object of the present invention is to provide a kind of Chinese medicine composition that is used for the treatment of rheumatic arthritis and its preparation method and application.
Technical scheme: the objective of the invention is to realize by following scheme:
A kind of Chinese medicine composition that is used for the treatment of rheumatic arthritis, it is prepared by the raw material of following parts by weight: Radix Angelicae Sinensis 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Radix Morindae Officinalis 40-60 part, Radix Polygoni Multiflori 10-20 part, Radix Paeoniae Alba 15-25 part, Radix Paeoniae Rubra 15-25 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Radix Dipsaci 10-20 part, Ramulus Uncariae Cum Uncis 10-20 part, Herba Epimedii 30-50 part, Cortex Albiziae 15-25 part, Pericarpium Citri Reticulatae 15-25 part, Semen Cuscutae 15-25 part, Fructus Corni 30-50 part, Radix Astragali 15-25 part, Poria 10-20 part, Radix Glycyrrhizae 10-20 part.
The above-mentioned Chinese medicine composition that is used for the treatment of rheumatic arthritis, it is prepared by the raw material of following parts by weight: 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Salviae Miltiorrhizaes, 45 parts of Radix Morindae Officinaliss, 15 parts of Radix Polygoni Multiflori, 20 parts of the Radix Paeoniae Albas, 20 parts of Radix Paeoniae Rubra, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Radix Dipsacis, 15 parts of Ramulus Uncariae Cum Uncis, 35 parts of Herba Epimedii, 20 parts of Cortex Albiziaes, 20 parts of Pericarpium Citri Reticulataes, 20 parts of Semen Cuscutae, 40 parts of Fructus Corni, 20 parts of the Radixs Astragali, 15 parts in Poria, 15 parts in Radix Glycyrrhizae.
The above-mentioned Chinese medicine composition that is used for the treatment of rheumatic arthritis, described raw material add adjuvant and make oral liquid, tablet, capsule or granule after extracting.
The above-mentioned Chinese medicine composition that is used for the treatment of rheumatic arthritis, described adjuvant are one or more of dextrin, lactose, starch, sucrose, glucose, microcrystalline Cellulose, mannose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose and stevioside.
The above-mentioned preparation method that is used for the treatment of the Chinese medicine composition of rheumatic arthritis, it is characterized in that, it comprises the steps: to get Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Morindae Officinalis, Radix Polygoni Multiflori, the Radix Paeoniae Alba, Radix Paeoniae Rubra, the Rhizoma Atractylodis Macrocephalae, Radix Dipsaci, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cortex Albiziae, Pericarpium Citri Reticulatae, Semen Cuscutae, Fructus Corni, the Radix Astragali, Poria, licorice medicinal materials merges, decoct with water twice, collecting decoction, relative density is the extractum of 1.15-1.20 when being evaporated to 65 ℃, adding ethanol makes the percent by volume that contains the alcohol amount reach 75-85%, stir, leave standstill, filter, relative density was 1.25-1.30 when filtrate decompression was concentrated into 65 ℃, and Recycled ethanol, get concentrated solution, concentrated solution is added water and adjuvant is mixed with oral liquid, or with the concentrated solution spray drying, add adjuvant and make capsule, tablet, granule.
The above-mentioned preparation method that is used for the treatment of the Chinese medicine composition of rheumatic arthritis, in the step, decocting condition is: the 8-12 that adds for the first time water and be medical material weight doubly measures, and decocts 1-2h, and the 6-10 that adds water for the second time and be medical material weight doubly measures, and decocts 1-2h.
The above-mentioned preparation method that is used for the treatment of the Chinese medicine composition of rheumatic arthritis, in the step, the spray drying condition is: inlet temperature is 100-120 ℃, leaving air temp is 80-90 ℃, temperature of charge is 70-90 ℃, and atomizing pressure is the 0.2-0.4 MPa, and spray velocity is 5-10ml/s.
The above-mentioned application of Chinese medicine composition in the medicine of preparation treatment rheumatic arthritis that is used for the treatment of rheumatic arthritis.
Beneficial effect:
1, Chinese medicine is thought human feeling's wind, cold, damp and is caused rheumatic arthritis, show as general pain or heavy sensation of the body, arthralgia, joint stuffiness, from theory of Chinese medical science, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Morindae Officinalis, Radix Polygoni Multiflori, the Radix Paeoniae Alba, Radix Astragali benefiting QI and nourishing blood among the we, be monarch drug, Radix Paeoniae Rubra, the Rhizoma Atractylodis Macrocephalae, Radix Dipsaci, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cortex Albiziae, Pericarpium Citri Reticulatae, Semen Cuscutae, Fructus Corni expelling wind and removing dampness, Poria, Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription are adjuvant, and all medicines are harmonious, play altogether benefiting QI and nourishing blood, expelling wind and removing dampness, expel wind to dredge collateral, the silt effect of dispelling of reducing phlegm are used for the treatment of rheumatic arthritis.
2, Formulation of the present invention is reasonable, and compatibility is rigorous, through long-term clinical verification, determined curative effect.
3, the present invention consists of Chinese crude drug, is the pharmacopeia kind, has no side effect low price.
The specific embodiment
Form by the following examples, foregoing of the present invention is described in further detail again, but this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example, all technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
1, Preparation Example
Embodiment 1: get Radix Angelicae Sinensis 10g, Radix Salviae Miltiorrhizae 20g, Radix Morindae Officinalis 40g, Radix Polygoni Multiflori 20g, Radix Paeoniae Alba 15g, Radix Paeoniae Rubra 25g, Rhizoma Atractylodis Macrocephalae 10g, Radix Dipsaci 20g, Ramulus Uncariae Cum Uncis 10g, Herba Epimedii 50g, Cortex Albiziae 15g, Pericarpium Citri Reticulatae 25g, Semen Cuscutae 15g, Fructus Corni 50g, Radix Astragali 15g, Poria 20g, Radix Glycyrrhizae 10g medical material merges, decoct with water twice, add for the first time 8 times of amounts that water is medical material weight, decoct 1h, add for the second time 6 times of amounts that water is medical material weight, decoct 1h, collecting decoction, 0.07MPa, relative density is 1.10 when being evaporated to 65 ℃ under 60-70 ℃, adding 95% (v/v) ethanol makes the alcohol amount of containing reach 85% (v/v), stir, left standstill 24 hours, decompression filtrate recycling ethanol is also concentrated, and filtrate is at 0.07MPa, relative density was 1.30 when concentrating under reduced pressure became to 65 ℃ under 65 ℃ of conditions, and (condition is that inlet temperature is 120 ℃ to spray drying, leaving air temp is 100 ℃, temperature of charge is 90 ℃, and atomizing pressure is 0.4 MPa, and spray velocity is 10ml/s.), adding starch, mix homogeneously with the moistening of an amount of 80% (v/v) ethanol, soft material processed, is crossed 30 mesh sieves and is granulated, and in 70 ~ 80 ℃ of dryings, with 60 mesh sieve granulate, tabletting, sugar coating, packing, outer package, censorship is qualified, gets tablet.
Embodiment 2: get 20 parts of Radix Angelicae Sinensis, 10 parts of Radix Salviae Miltiorrhizaes, 60 parts of Radix Morindae Officinaliss, 10 parts of Radix Polygoni Multiflori, 25 parts of the Radix Paeoniae Albas, 15 parts of Radix Paeoniae Rubra, 20 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Dipsacis, 20 parts of Ramulus Uncariae Cum Uncis, 30 parts of Herba Epimedii, 25 parts of Cortex Albiziaes, 15 parts of Pericarpium Citri Reticulataes, 25 parts of Semen Cuscutae, 30 parts of Fructus Corni, 25 parts of the Radixs Astragali, 10 parts in Poria, 20 parts of medical materials of Radix Glycyrrhizae merge, decoct with water twice, add for the first time 10 times of amounts that water is medical material weight, decoct 1.5h, add for the second time 8 times of amounts that water is medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, relative density is 1.15 when being evaporated to 65 ℃ under 60-70 ℃, adding 95% (v/v) ethanol makes the alcohol amount of containing reach 75% (v/v), stir, left standstill 24 hours, decompression filtrate recycling ethanol is also concentrated, and filtrate is at 0.07MPa, relative density was 1.25 when concentrating under reduced pressure became to 65 ℃ under 65 ℃ of conditions, and (condition is that inlet temperature is 100 ℃ to spray drying, leaving air temp is 80 ℃, temperature of charge is 80 ℃, and atomizing pressure is 0.2 MPa, and spray velocity is 5ml/s.), adding dextrin etc., dry granulation is crossed 60 mesh sieves, and No. 1 capsule of packing into gets final product to get capsule.
Embodiment 3: get Poria 20g, Poria cum Radix Pini 10g, Caulis Polygoni Multiflori 60g, Rhizoma Cyperi 10g, Rhizoma Atractylodis Macrocephalae 25g, Radix Paeoniae Rubra 15g, Radix Paeoniae Alba 20g, Pericarpium Citri Reticulatae 10g, Herba Taxilli 20g, Semen Coicis 30g, Fructus Corni 25g, Radix Achyranthis Bidentatae 15g, Radix Dipsaci 25g, Endothelium Corneum Gigeriae Galli 30g, Radix Aucklandiae 25g, Radix Bupleuri 10g, Fructus Hordei Germinatus 30g, Radix Glycyrrhizae 10g medical material merges, decoct with water twice, add for the first time 12 times of amounts that water is medical material weight, decoct 2h, add for the second time 10 times of amounts that water is medical material weight, decoct 2h, collecting decoction, 0.07MPa, relative density is 1.15 when being evaporated to 65 ℃ under 60-70 ℃, adding 95% (v/v) ethanol makes the alcohol amount of containing reach 75% (v/v), stir, left standstill 24 hours, decompression filtrate recycling ethanol is also concentrated, and filtrate is at 0.07MPa, relative density was 1.25 when concentrating under reduced pressure became to 65 ℃ under 65 ℃ of conditions, and (condition is that inlet temperature is 110 ℃ to spray drying, leaving air temp is 85 ℃, temperature of charge is 85 ℃, and atomizing pressure is 0.3 MPa, and spray velocity is 7.5ml/s.), add above-mentioned Benexate Hydrochloride, pulverize, add again suitable lactose, with the moistening of an amount of 80% (v/v) ethanol, soft material processed, cross 14 mesh sieves and granulate, 50-80 ℃ of drying, 60 order granulate get granule.
Embodiment 4: get Radix Angelicae Sinensis 15g, Radix Salviae Miltiorrhizae 15g, Radix Morindae Officinalis 45g, Radix Polygoni Multiflori 15g, Radix Paeoniae Alba 20g, Radix Paeoniae Rubra 20g, Rhizoma Atractylodis Macrocephalae 15g, Radix Dipsaci 15g, Ramulus Uncariae Cum Uncis 15g, Herba Epimedii 35g, Cortex Albiziae 20g, Pericarpium Citri Reticulatae 20g, Semen Cuscutae 20g, Fructus Corni 40g, Radix Astragali 20g, Poria 15g, Radix Glycyrrhizae 15g medical material merges, decoct with water twice, add for the first time 10 times of amounts that water is medical material weight, decoct 1.5h, add for the second time 8 times of amounts that water is medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, relative density is 1.15 when being evaporated to 65 ℃ under 60-70 ℃, adding 95% (v/v) ethanol makes the alcohol amount of containing reach 75% (v/v), stir, left standstill 24 hours, decompression filtrate recycling ethanol is also concentrated, and filtrate is at 0.07MPa, relative density was 1.25 when concentrating under reduced pressure became to 65 ℃ under 65 ℃ of conditions, add water and sucrose, be prepared into oral liquid.
2. the present invention treats the experimentation of rheumatic arthritis
2.1 the preparation of sample: press the preparation of oral liquid embodiment method, namely get Radix Angelicae Sinensis 15g, Radix Salviae Miltiorrhizae 15g, Radix Morindae Officinalis 45g, Radix Polygoni Multiflori 15g, Radix Paeoniae Alba 20g, Radix Paeoniae Rubra 20g, Rhizoma Atractylodis Macrocephalae 15g, Radix Dipsaci 15g, Ramulus Uncariae Cum Uncis 15g, Herba Epimedii 35g, Cortex Albiziae 20g, Pericarpium Citri Reticulatae 20g, Semen Cuscutae 20g, Fructus Corni 40g, Radix Astragali 20g, Poria 15g, Radix Glycyrrhizae 15g medical material merges, decoct with water twice, add for the first time 10 times of amounts that water is medical material weight, decoct 1.5h, add for the second time 8 times of amounts that water is medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, relative density is 1.15 when being evaporated to 65 ℃ under 60-70 ℃, adding 95% (v/v) ethanol makes the alcohol amount of containing reach 75% (v/v), stir, left standstill 24 hours, decompression filtrate recycling ethanol is also concentrated, and filtrate is at 0.07MPa, relative density was 1.25 when concentrating under reduced pressure became to 65 ℃ under 65 ℃ of conditions, added water and sucrose, be prepared into 20 of oral liquids, every contains crude drug amount 18g.
2.2 dosage: according to " the dose,equivalent ratio table of converting by the surface between humans and animals ", every day, 70 kilograms of people's consumption was 54g, every day, the consumption of every 20g mice was 54*0.0026=0.08g, be 18g because every oral liquid 10ml contains the crude drug amount, the consumption that is every mice is 0.1ml, for ease of administration, low dose of gavage 0.1ml oral liquid, dosage and high dose difference gavage 0.2ml and 0.4ml namely, the oral liquid of every 20g mouse stomach contained the crude drug amount and was respectively 0.18g, 0.36g, 0.72g every day, then press the Mice Body restatement, low dosage, middle dosage and high dose are respectively 9g crude drug amount/kg, 18g crude drug amount/kg and 36g crude drug amount/kg.
2.3 instrument and reagent
DKZ-2 type electric heating constant-temperature water-bath tank (the upper grand experimental facilities company limited of Nereid), 8452A type ultraviolet spectrophotometer (hewlette-packard); TG328A type photoelectric analytical balance (Shanghai balance equipment factory).Glacial acetic acid (Shanghai reagent four factories, lot number: 090402) aspirin tablet, Nanjing Pharmaceutical Plant, lot number 20100216
2.3 210 of animal Kunming mouses are female, body weight (20.1 ± 2.4) g provides (SYXK (Soviet Union) 2000-0053) by Nanjing University of Traditional Chinese Medicine's Experimental Animal Center.
2.4 analgesic activity (hot plate method) experiment
2.4.1 grouping and administration divide 5 groups at random with 50 mices, i.e. negative control group, positive controls, the large, medium and small dosage group of the present invention, and every group is 10; Next day gastric infusion, continuous 7d, the large, medium and small dosage of the present invention; Positive controls is to aspirin tablet, and dosage is 20gkg-1d-1; Negative control group gavage 0.9% sodium chloride solution, volume is every 2ml, carries out analgesic activity (hot plate method) experiment behind the drug withdrawal 24h.
2.4.2 with the water bath topped up with water, make water surface contact hot plate, the regulating thermostatic device makes water temperature be controlled at 55 ± 0.5 ℃, heating is rear as thermostimulation, (survey 2 times as the pain threshold of this Mus to occurring licking the sufficient time (s) from dropping into hot plate with stopwatch record mice, be no more than 60 seconds persons as qualified take meansigma methods), in administration 1h after the 3rd day, survey again every pain threshold.
2.5 analgesic activity (writhing method) experiment
2.5.1 grouping and administration divide 5 groups at random with 50 mices, i.e. negative control group, positive controls, the large, medium and small dosage group of the present invention, and every group is 10; Next day gastric infusion, continuous 7d, the large, medium and small dosage of the present invention is respectively 40,20,10gkg-1d-1 (quite crude drug); Positive controls is to aspirin tablet, and dosage is 20gkg-1d-1; Negative control group gavage 0.9% sodium chloride solution, volume is every 2ml, carries out analgesic activity (writhing method) experiment behind the drug withdrawal 24h.
2.5.2 after the administration in the 3rd day 1 hour, every Mus lumbar injection 0.6% glacial acetic acid 0.1ml/10g, each Mus writhing number of times, relatively group difference in the 10min behind the record injection algogen.
Table 1 the present invention is on the impact of mice analgesic activity (x ± s)
Compare * 1P＜0.01, * 2P＜0.05 with negative control group
2.6 granulation tissue hyperplasia test
2.6.1 grouping and experiment divide 5 groups at random with 50 mices, i.e. model group, positive controls, the large, medium and small dosage group of the present invention, and every group is 10, adopts cotton balls oxter burying storage modeling.
2.6.2 administration gastric infusion next day, continuous 7d, the large, medium and small dosage of the present invention; Positive controls is the same; Model group gavage 0.9% sodium chloride solution, volume is every 2ml, and 30min after the last administration with sacrifice of animal, takes out the cotton balls granulation tissue, dries in 60 ℃ of baking boxs and weighs.Deduct the cotton balls quality with cotton balls granulation tissue dry weight, be the granulation tissue net weight.
Table 2 the present invention buries the impact of bringing out granulation tissue hyperplasia (x ± s) to mice oxter cotton balls
Compare * 1P＜0.01, * 2P＜0.05 with negative control group
2.7 experiment conclusion
2.7.1 the big-and-middle dosed administration group of the present invention can improve the mice pain threshold and reduce acetic acid induced mice writhing number of times, compares with negative control group, and significant difference (P＜0.05 or P＜0.01) is arranged, and shows that the present invention has obvious analgesic activity.Size dosed administration group can alleviate granulation tissue weight, the cotton balls oxter is buried bring out granulation tissue hyperplasia obvious inhibitory action is arranged, and with negative control group significant difference (P＜0.01, P＜0.05) is arranged relatively, shows that the present invention has obvious antiinflammatory action.To sum up, the present invention has certain therapeutical effect to rheumatic arthritis.
Claims (8)
1. Chinese medicine composition that is used for the treatment of rheumatic arthritis, it is characterized in that it is prepared by the raw material of following parts by weight: Radix Angelicae Sinensis 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Radix Morindae Officinalis 40-60 part, Radix Polygoni Multiflori 10-20 part, Radix Paeoniae Alba 15-25 part, Radix Paeoniae Rubra 15-25 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Radix Dipsaci 10-20 part, Ramulus Uncariae Cum Uncis 10-20 part, Herba Epimedii 30-50 part, Cortex Albiziae 15-25 part, Pericarpium Citri Reticulatae 15-25 part, Semen Cuscutae 15-25 part, Fructus Corni 30-50 part, Radix Astragali 15-25 part, Poria 10-20 part, Radix Glycyrrhizae 10-20 part.
2. the Chinese medicine composition that is used for the treatment of rheumatic arthritis according to claim 1, it is characterized in that it is prepared by the raw material of following parts by weight: 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Salviae Miltiorrhizaes, 45 parts of Radix Morindae Officinaliss, 15 parts of Radix Polygoni Multiflori, 20 parts of the Radix Paeoniae Albas, 20 parts of Radix Paeoniae Rubra, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Radix Dipsacis, 15 parts of Ramulus Uncariae Cum Uncis, 35 parts of Herba Epimedii, 20 parts of Cortex Albiziaes, 20 parts of Pericarpium Citri Reticulataes, 20 parts of Semen Cuscutae, 40 parts of Fructus Corni, 20 parts of the Radixs Astragali, 15 parts in Poria, 15 parts in Radix Glycyrrhizae.
3. the Chinese medicine composition that is used for the treatment of rheumatic arthritis according to claim 1 and 2 is characterized in that, described raw material adds adjuvant and makes oral liquid, tablet, capsule or granule after extracting.
4. the Chinese medicine composition that is used for the treatment of rheumatic arthritis according to claim 3, it is characterized in that described adjuvant is one or more of dextrin, lactose, starch, sucrose, glucose, microcrystalline Cellulose, mannose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose and stevioside.
5. claim 1 or the 2 described preparation methoies that are used for the treatment of the Chinese medicine composition of rheumatic arthritis, it is characterized in that, it comprises the steps: to get Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Morindae Officinalis, Radix Polygoni Multiflori, the Radix Paeoniae Alba, Radix Paeoniae Rubra, the Rhizoma Atractylodis Macrocephalae, Radix Dipsaci, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cortex Albiziae, Pericarpium Citri Reticulatae, Semen Cuscutae, Fructus Corni, the Radix Astragali, Poria, licorice medicinal materials merges, decoct with water twice, collecting decoction, relative density is the extractum of 1.15-1.20 when being evaporated to 65 ℃, adding ethanol makes the percent by volume that contains the alcohol amount reach 75-85%, stir, leave standstill, filter, relative density was 1.25-1.30 when filtrate decompression was concentrated into 65 ℃, and Recycled ethanol, get concentrated solution, concentrated solution is added water and adjuvant is mixed with oral liquid, or with the concentrated solution spray drying, add adjuvant and make capsule, tablet, granule.
6. the preparation method that is used for the treatment of the Chinese medicine composition of rheumatic arthritis according to claim 5 is characterized in that, in the step, decocting condition is: the 8-12 that adds for the first time water and be medical material weight doubly measures, decoct 1-2h, the 6-10 that adds water for the second time and be medical material weight doubly measures, and decocts 1-2h.
7. the preparation method that is used for the treatment of the Chinese medicine composition of rheumatic arthritis according to claim 5, it is characterized in that, in the step, the spray drying condition is: inlet temperature is 100-120 ℃, leaving air temp is 80-90 ℃, temperature of charge is 70-90 ℃, and atomizing pressure is the 0.2-0.4 MPa, and spray velocity is 5-10ml/s.
8. claim 1 or the 2 described application of Chinese medicine composition in the medicine of preparation treatment rheumatic arthritis that are used for the treatment of rheumatic arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210523876.5A CN102935133B (en) | 2012-12-08 | 2012-12-08 | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210523876.5A CN102935133B (en) | 2012-12-08 | 2012-12-08 | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102935133A true CN102935133A (en) | 2013-02-20 |
| CN102935133B CN102935133B (en) | 2014-07-23 |
Family
ID=47694080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210523876.5A Expired - Fee Related CN102935133B (en) | 2012-12-08 | 2012-12-08 | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102935133B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800759A (en) * | 2015-04-30 | 2015-07-29 | 淄博齐鼎立专利信息咨询有限公司 | Traditional Chinese medicine composition for treating rheumatic arthritis |
| CN105296156A (en) * | 2015-11-13 | 2016-02-03 | 李洋 | Extraction method and applications of camphor wood oil essence |
| CN105663789A (en) * | 2016-03-03 | 2016-06-15 | 冯字 | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof |
| CN107384643A (en) * | 2017-09-01 | 2017-11-24 | 南京晶云化工有限公司 | A kind of antipruritic perfumed soap and preparation method thereof |
| CN115957260A (en) * | 2022-10-26 | 2023-04-14 | 山西中医药大学 | Traditional Chinese medicine composition with dampness removing and anti-inflammatory functions as well as preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009062301A (en) * | 2007-09-05 | 2009-03-26 | Tropical Technology Center Ltd | Essence of morinda citrifolia l. and use thereof |
| CN101744895A (en) * | 2008-12-03 | 2010-06-23 | 李国强 | Medical preparation for treatment of rheumatism, lumbar vertebra disease and cervical spondylosis |
| CN101961477A (en) * | 2009-07-22 | 2011-02-02 | 靳环杰 | Rheumatic bone ache medicine |
| CN102302555A (en) * | 2011-09-21 | 2012-01-04 | 中国人民解放军第二军医大学 | Chinese medicinal extract for treating urarthritis, as well as preparation method and application thereof |
| WO2012101741A1 (en) * | 2011-01-24 | 2012-08-02 | 株式会社資生堂 | Tie-2 activator, agent for maturation, normalization, or stabilization of blood vessels, lymph vessel stabilizing agent, wrinkle prevention/improvement agent, and edema improvement/prevention agent |
| CN102657710A (en) * | 2011-12-13 | 2012-09-12 | 吴新治 | Medicament for treating backache and lumbar disc herniation by renewing muscles and bones and method for preparing the same |
-
2012
- 2012-12-08 CN CN201210523876.5A patent/CN102935133B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009062301A (en) * | 2007-09-05 | 2009-03-26 | Tropical Technology Center Ltd | Essence of morinda citrifolia l. and use thereof |
| CN101744895A (en) * | 2008-12-03 | 2010-06-23 | 李国强 | Medical preparation for treatment of rheumatism, lumbar vertebra disease and cervical spondylosis |
| CN101961477A (en) * | 2009-07-22 | 2011-02-02 | 靳环杰 | Rheumatic bone ache medicine |
| WO2012101741A1 (en) * | 2011-01-24 | 2012-08-02 | 株式会社資生堂 | Tie-2 activator, agent for maturation, normalization, or stabilization of blood vessels, lymph vessel stabilizing agent, wrinkle prevention/improvement agent, and edema improvement/prevention agent |
| CN102302555A (en) * | 2011-09-21 | 2012-01-04 | 中国人民解放军第二军医大学 | Chinese medicinal extract for treating urarthritis, as well as preparation method and application thereof |
| CN102657710A (en) * | 2011-12-13 | 2012-09-12 | 吴新治 | Medicament for treating backache and lumbar disc herniation by renewing muscles and bones and method for preparing the same |
Non-Patent Citations (2)
| Title |
|---|
| 袁德培等: "复方竹节参片治疗类风湿性关节炎30例临床观察", 《中国中医药科技》 * |
| 闻辉: "路志正痹证治验", 《中国社区医师》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800759A (en) * | 2015-04-30 | 2015-07-29 | 淄博齐鼎立专利信息咨询有限公司 | Traditional Chinese medicine composition for treating rheumatic arthritis |
| CN105296156A (en) * | 2015-11-13 | 2016-02-03 | 李洋 | Extraction method and applications of camphor wood oil essence |
| CN105663789A (en) * | 2016-03-03 | 2016-06-15 | 冯字 | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof |
| CN107384643A (en) * | 2017-09-01 | 2017-11-24 | 南京晶云化工有限公司 | A kind of antipruritic perfumed soap and preparation method thereof |
| CN115957260A (en) * | 2022-10-26 | 2023-04-14 | 山西中医药大学 | Traditional Chinese medicine composition with dampness removing and anti-inflammatory functions as well as preparation method and application thereof |
| CN115957260B (en) * | 2022-10-26 | 2024-02-02 | 山西中医药大学 | Traditional Chinese medicine composition for dispelling wind-damp and resisting inflammation, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102935133B (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101987123B (en) | Medicament for easing pain of human body and preparation method thereof | |
| CN100384467C (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN101987122A (en) | Medicament for easing pain of human body and preparation method thereof | |
| CN102935133B (en) | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof | |
| CN101129593A (en) | Traditional Chinese medicine for treating senility habitual constipation | |
| CN103341145A (en) | Traditional Chinese medicine for treating psoriasis and preparation method thereof | |
| CN101708297A (en) | Medicament for treating gout disease | |
| CN104258292A (en) | Drug for department of obstetrics and gynecology for treating pregnancy complication and manufacturing method thereof | |
| CN104800759A (en) | Traditional Chinese medicine composition for treating rheumatic arthritis | |
| CN101129971B (en) | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same | |
| CN102727753B (en) | Traditional Chinese medicine composition used for treating gout, and preparation method and application thereof | |
| CN108543044B (en) | Combined medicine for treating acne and application thereof | |
| CN103127357A (en) | Traditional Chinese medicine composition used for treating kidney stone, and preparation method and application thereof | |
| CN102935195B (en) | Traditional Chinese medicine composition for treating coronary heart disease as well as preparation method and application thereof | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN101543577A (en) | Traditional Chinese medicine composition for curing whelk and preparation method thereof | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN101129893A (en) | Traditional Chinese medicine for treating cervical vertebra disease combined with diarrhea | |
| CN103919966A (en) | Medicament for treating acne | |
| CN102973820A (en) | Granules of Chinese patent drug for treating rheumatic and rheumatoid arthritis | |
| CN102228591A (en) | Preparation method of oral medicinal preparation for regulating menstruation and stopping pains | |
| CN102204978A (en) | Medicinal composition for treating cancer pain and preparation thereof | |
| CN104306784A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis as well as preparation method and application thereof | |
| CN104998225A (en) | Medicinal preparation for treatment of constipation | |
| CN100340272C (en) | Headache-treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GANSU MINXIAN KANGDA PHARMACEUTICAL DEVELOPMENT CO Free format text: FORMER OWNER: NANJING ZHENGKUAN PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. Effective date: 20140625 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gan Dequan Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: REQUEST NOT TO RELEASE THE NAME TO: GAN DEQUAN Free format text: CORRECT: ADDRESS; FROM: 211224 NANJING, JIANGSU PROVINCE TO: 748411 DINGXI, GANSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140625 Address after: 748411 Minxian Town, ten li, Dingxi, Gansu Applicant after: GANSU MINXIAN KANGDA PHARMACEUTICAL DEVELOPMENT CO., LTD. Address before: 211224 No. 1 Industrial Park, Jing Qiao Town, Lishui County, Jiangsu, Nanjing Applicant before: Nanjing Zhengkuan Pharmaceutical Science and Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140723 Termination date: 20161208 |